282 related articles for article (PubMed ID: 33721736)
1. Deep learning model for virtual screening of novel 3C-like protease enzyme inhibitors against SARS coronavirus diseases.
Kumari M; Subbarao N
Comput Biol Med; 2021 May; 132():104317. PubMed ID: 33721736
[TBL] [Abstract][Full Text] [Related]
2. Development of a deep learning-based quantitative structure-activity relationship model to identify potential inhibitors against the 3C-like protease of SARS-CoV-2.
Kumari M; Subbarao N
Future Med Chem; 2022 Nov; 14(21):1541-1559. PubMed ID: 36177879
[No Abstract] [Full Text] [Related]
3. QSAR modeling and pharmacoinformatics of SARS coronavirus 3C-like protease inhibitors.
Ishola AA; Adedirin O; Joshi T; Chandra S
Comput Biol Med; 2021 Jul; 134():104483. PubMed ID: 34020129
[TBL] [Abstract][Full Text] [Related]
4. Virtual screening of anti-HIV1 compounds against SARS-CoV-2: machine learning modeling, chemoinformatics and molecular dynamics simulation based analysis.
Nand M; Maiti P; Joshi T; Chandra S; Pande V; Kuniyal JC; Ramakrishnan MA
Sci Rep; 2020 Nov; 10(1):20397. PubMed ID: 33230180
[TBL] [Abstract][Full Text] [Related]
5. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.
Kumar V; Roy K
SAR QSAR Environ Res; 2020 Jul; 31(7):511-526. PubMed ID: 32543892
[TBL] [Abstract][Full Text] [Related]
6. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.
Wang S; Sun Q; Xu Y; Pei J; Lai L
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34081143
[TBL] [Abstract][Full Text] [Related]
7. Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants.
Muhammad I; Rahman N; Gul-E-Nayab ; Niaz S; Basharat Z; Rastrelli L; Jayanthi S; Efferth T; Khan H
Comput Biol Med; 2021 Jun; 133():104362. PubMed ID: 33894500
[TBL] [Abstract][Full Text] [Related]
8. Determination of Novel SARS-CoV-2 Inhibitors by Combination of Machine Learning and Molecular Modeling Methods.
Güner E; Özkan Ö; Yalcin-Ozkat G; Ölgen S
Med Chem; 2024; 20(2):153-231. PubMed ID: 37957860
[TBL] [Abstract][Full Text] [Related]
9. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
[TBL] [Abstract][Full Text] [Related]
10. Developing a SARS-CoV-2 main protease binding prediction random forest model for drug repurposing for COVID-19 treatment.
Liu J; Xu L; Guo W; Li Z; Khan MKH; Ge W; Patterson TA; Hong H
Exp Biol Med (Maywood); 2023 Nov; 248(21):1927-1936. PubMed ID: 37997891
[TBL] [Abstract][Full Text] [Related]
11. Computational investigation of drug bank compounds against 3C-like protease (3CL
Joshi T; Sharma P; Mathpal S; Joshi T; Maiti P; Nand M; Pande V; Chandra S
Mol Divers; 2022 Aug; 26(4):2243-2256. PubMed ID: 34637068
[TBL] [Abstract][Full Text] [Related]
12. Predictive modeling by deep learning, virtual screening and molecular dynamics study of natural compounds against SARS-CoV-2 main protease.
Joshi T; Joshi T; Pundir H; Sharma P; Mathpal S; Chandra S
J Biomol Struct Dyn; 2021 Oct; 39(17):6728-6746. PubMed ID: 32752947
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.
Kadioglu O; Saeed M; Greten HJ; Efferth T
Comput Biol Med; 2021 Jun; 133():104359. PubMed ID: 33845270
[TBL] [Abstract][Full Text] [Related]
14. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
Mandour YM; Zlotos DP; Alaraby Salem M
J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
[TBL] [Abstract][Full Text] [Related]
15. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
[TBL] [Abstract][Full Text] [Related]
16. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
[TBL] [Abstract][Full Text] [Related]
17. Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study.
Gentile D; Patamia V; Scala A; Sciortino MT; Piperno A; Rescifina A
Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32340389
[TBL] [Abstract][Full Text] [Related]
18. In-silico studies of inhibitory compounds against protease enzymes of SARS-CoV-2.
Khan S; Nasrullah ; Hussain A; Asif M; Sattar FA; Audhal FA; Qadir MI; Hamdard MH
Medicine (Baltimore); 2023 Feb; 102(6):e31318. PubMed ID: 36820539
[TBL] [Abstract][Full Text] [Related]
19. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
[TBL] [Abstract][Full Text] [Related]
20. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M
Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y
Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
